In a large multicenter prospective trial [1], in which 672 cancer patients were randomly assigned to receive LMWH or oral anticoagulant therapy (OAT) for 6 months, a statistically significant improvement in overall survival (death for any cause at 12 months) in favor of dalteparin over OAT was demonstrated in patients affected by non-metastatic disease (hazard ratio, 0.50; 95% CI, 0.27-0.95; P = 0.03) [2]. These authors used all-cause mortality rather than cancer-related mortality. For this reason, we performed a literature-based pooled analysis to summarize the results of the randomized trials concerning cancer-related death during anticoagulant therapy and follow-up in cancer patients receiving LWMH or OAT (Table 1) . Event-based relative risk (RR) ratios with 95% CIs were derived. Combined-effect estimation was computed with both random-and fixed-effect models. A heterogeneity test was applied as well.
None of these studies was primarily designed to investigate the effect of LMWH or OAT on cancer-related mortality, because the primary question in many of them was addressing recurrent VTE. The pitfalls of this type of analysis, including the concept of combining different cancers at different stages and biologic activity, and the discrepancies among studies in anticoagulant therapy dosage and duration must be taken into account: the CLOT trial [1] reported on the mortality of patients treated for 6 months, whereas the other studies treated patients for 3-6 months [3-9, 13]. Moreover, when Lee et al. [2] separated out the good prognosis cancer patients, a statistically significant difference in mortality was seen at 1 year.
However, the absence of a significant heterogeneity (P = 0.97) suggests the consistency of these results. Thus, the putative antineoplastic effect exerted by LMWH in cancer patients remains still controversial. Further large clinical trials still need to be run in order to address this fascinating issue. Kakkar et al. [13] Lee et al. 
